Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
On July 10, the U.S. Senate killed legislation that sought to limit non-economic damage recoveries in medical malpractice suits to $250,000. It would also have capped punitive damages at the greater of $250,000 or twice the amount of economic damages. The vote was 49-48, with Republicans largely favoring it and Democrats opposing it. President Bush, who was pushing for passage of the bill, stated after the vote that he was dismayed by the outcome because access to quality health care is being jeopardized by frivolous lawsuits. The bill was similar to one passed by Congress earlier this year.
New Jersey Plaintiffs Lose Right to Interest
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
Why is it that those who are best skilled at advocating for others are ill-equipped at advocating for their own skills and what to do about it?
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
Active reading comprises many daily tasks lawyers engage in, including highlighting, annotating, note taking, comparing and searching texts. It demands more than flipping or turning pages.
With trillions of dollars to keep watch over, the last thing we need is the distraction of costly litigation brought on by patent assertion entities (PAEs or "patent trolls"), companies that don't make any products but instead seek royalties by asserting their patents against those who do make products.